MentionFox
Home › Executive changes › Mersana Therapeutics, Inc.
Leadership changes · MRSN · SEC Form 8-K, Item 5.02

Leadership changes at Mersana Therapeutics, Inc. (2026)

Before you join, sell to or invest in Mersana Therapeutics, Inc.

MentionFox check on Mersana Therapeutics, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/mersana-therapeutics

  • Note: Layoff plan disclosed May 2025 (filing)

New since last check: Layoff plan disclosed May 2025 (filing, first seen 14 November 2026).

Check Mersana Therapeutics, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Mersana Therapeutics, Inc.?

Who joined and who left Mersana Therapeutics, Inc. (MRSN)? 1 filing reported on 2026-01-06, each cited to the company's own filing.

As of November 14, 2026, Mersana Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on January 6, 2026 (Form 8-K, January 6, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Bain Capital Life Sciences Fund II, L.P. also filed stake reports on 2 other companies ↓

Sell to companies like Mersana Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-01-06

Mersana Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-01-06. Every row below is cited to the filing it comes from, and this page adds each new change as Mersana Therapeutics, Inc. files it.

Layoffs on record: 1 filing or notice, latest 2025-05-06 (layoff filings and notices).

Also on the record for Mersana Therapeutics, Inc.

DateRecordFigureOur pageSource
May 15, 2026Stake report, Schedule 13G/A, by 683 Capital Management, LLC—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by 683 Capital Management, LLC7.03% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Schonfeld Strategic Advisors LLC—5%+ stakesSource
January 30, 2026Stake report, Schedule 13G/A, by The Vanguard Group4.2% of the class5%+ stakesSource
January 9, 2026Stake report, Schedule 13G/A, by Nextech Crossover I GP S.a. r.l.—5%+ stakesSource
January 8, 2026Stake report, Schedule 13D/A, by Bain Capital Life Sciences Fund II, L.P.—5%+ stakesSource
January 6, 2026Acquired by Day One Biopharmaceuticals, Inc.—AcquisitionSource
November 24, 2025Stake report, Schedule 13G, by 683 Capital Management, LLC5.47% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G, by Schonfeld Strategic Advisors LLC5.48% of the class5%+ stakesSource
November 13, 2025Stake report, Schedule 13D/A, by Bain Capital Life Sciences Fund II, L.P.4% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by Schonfeld Strategic Advisors LLC4.55% of the class5%+ stakesSource
July 17, 2025Stake report, Schedule 13G/A, by BlackRock, Inc.3% of the class5%+ stakesSource

Selling to them or working with them? See who runs Mersana Therapeutics, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Mersana Therapeutics, Inc. and the records around it.

Mersana Therapeutics, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Mersana Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Mersana Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Mersana Therapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-01-06Reportednot named in the filing8-K, 2026-01-06
Selling to Mersana Therapeutics, Inc.?

New leaders reset buying decisions — get the Full Report on Mersana Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Mersana Therapeutics, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Mersana Therapeutics, Inc., with the record behind each one.

Find candidates like senior executive at Mersana Therapeutics, Inc.

Every change, in the filing's words

Filed 2026-01-06 · 8-K

Reported

In accordance with the terms of the Merger Agreement, (i) each of Lawrence M. Alleva, William H. Dere, Allene M. Diaz, Andrew A. F. Hack, Kristen M. Hege, Martin Huber, David Mott and Anna Protopapas resigned from his or her respective position as a member of the Company's board of directors and all committees thereof, effective as of the Effective Time and (ii) Charles N. York II and Adam Dubow, each a director of Purchaser immediately prior to the Effective Time, became directors of the Company, in each case, effective as of the Effective Time.

Also stated in this filing

  • These resignations were tendered in connection with the Merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies or practices.
  • In accordance with the terms of the Merger Agreement, each officer of Purchaser immediately prior to the Effective Time became an officer of the Company effective as of the Effective Time.
  • The officers of Purchaser immediately prior to the Effective Time were Charles N. York II as Chief Executive Officer, President, Chief Financial Officer, Chief Operating Officer and Treasurer and Adam Dubow as Chief Compliance Officer, General Counsel and Secretary.
  • Effective immediately following completion of the Merger, all of the incumbent officers of the Company, as of immediately prior to the Effective Time, ceased being officers of the Company.

Tools for this story

Each opens in a new tab, filled in for Mersana Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/mersana-therapeutics
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Mersana Therapeutics, Inc.?. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/mersana-therapeutics